Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2018 Filed Oct 18, 2019 13:40 UTC |
Mona Joseph10% owner
|
PurchaseMicrobot Medical Common Stock | 24,873 | $2.21 | $54,969.33 |
DisclosureSEC source: 0001791387-19-000001 · primary_doc.xml · nonDerivative · entry 2 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,971 Read SEC document |
| November 19, 2018 Filed Oct 18, 2019 13:40 UTC |
Mona Joseph10% owner
|
PurchaseMicrobot Medical Common Stock | 2,400 | $2.99 | $7,176.00 |
DisclosureSEC source: 0001791387-19-000001 · primary_doc.xml · nonDerivative · entry 1 Mona Joseph · CIK 0001791387 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,971 Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 21:49 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 35,000 | $1.06 | $37,191.00 |
DisclosureSEC source: 0001493152-18-000421 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,530,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 35,000 shares of Issuer common stock on January 9, 2018. Accordingly, Reporting Person beneficially owned 4,530,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 18:55 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 2,868 | $1.01 | $2,884.06 |
DisclosureSEC source: 0001493152-18-000142 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,565,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 2,868 shares of Issuer common stock on January 3, 2018. Accordingly, Reporting Person beneficially owned 4,565,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:12 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 42,132 | $1.01 | $42,515.40 |
DisclosureSEC source: 0001493152-18-000089 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,568,277 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 42,132 shares of Issuer common stock on January 2, 2018. Accordingly, Reporting Person beneficially owned 4,568,277 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 28, 2017 Filed Jan 24, 2018 18:32 UTC |
Naim David BenChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001493152-18-000959 · form4.xml · derivative · entry 1 Naim David Ben · CIK 0001692130 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.01 per share · 75,000 shares Expires 2027-12-28 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 27, 2017 Filed Dec 28, 2017 18:21 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 14,257 | $1.02 | $14,573.51 |
DisclosureSEC source: 0001493152-17-015176 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,610,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 14,257 shares of Issuer common stock on December 27, 2017. Accordingly, Reporting Person beneficially owned 4,610,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 26, 2017 Filed Dec 27, 2017 21:32 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 30,743 | $1.02 | $31,416.27 |
DisclosureSEC source: 0001493152-17-015110 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,624,666 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 30,743 shares of Issuer common stock on December 26, 2017. Accordingly, Reporting Person beneficially owned 4,624,666 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:03 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 12,933 | $1.03 | $13,328.75 |
DisclosureSEC source: 0001493152-17-014953 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,655,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on December 19, 2017 and December 20, 2017. Accordingly, Reporting Person beneficially owned 4,655,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 22:03 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 32,067 | $1.03 | $33,029.01 |
DisclosureSEC source: 0001493152-17-014953 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,655,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on December 19, 2017 and December 20, 2017. Accordingly, Reporting Person beneficially owned 4,655,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 17:55 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 841 | $1.02 | $857.82 |
DisclosureSEC source: 0001493152-17-014589 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,700,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 841 shares of Issuer common stock on December 13, 2017. Accordingly, Reporting Person beneficially owned 4,700,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 21:44 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 44,159 | $1.04 | $45,801.71 |
DisclosureSEC source: 0001493152-17-014564 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,701,250 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 44,159 shares of Issuer common stock on December 12, 2017. Accordingly, Reporting Person beneficially owned 4,701,250 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 06, 2017 Filed Dec 7, 2017 23:22 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 15,375 | $1.05 | $16,157.59 |
DisclosureSEC source: 0001493152-17-014345 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,745,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 15,375 shares of Issuer common stock on December 6, 2017. Accordingly, Reporting Person beneficially owned 4,745,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:12 UTC |
Waizer Yoav ZviDirector
|
GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014429 · form4.xml · derivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:09 UTC |
Madden Martin J.Director
|
GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014426 · form4.xml · derivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:07 UTC |
Burell Scott RDirector
|
GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014423 · form4.xml · derivative · entry 1 Burell Scott R · CIK 0001399318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:05 UTC |
Bornstein YosephDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014419 · form4.xml · derivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 17:55 UTC |
Waizer Yoav ZviDirector
|
SaleCommon Stock | 10,000 | $1.08 | $10,800.00 |
DisclosureSEC source: 0001493152-17-014245 · form4.xml · nonDerivative · entry 2 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 23:29 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 29,625 | $1.08 | $32,128.31 |
DisclosureSEC source: 0001493152-17-014280 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,760,784 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 29,625 shares of Issuer common stock on December 5, 2017. Accordingly, Reporting Person beneficially owned 4,760,784 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 17:55 UTC |
Waizer Yoav ZviDirector
|
PurchaseCommon Stock | 10,000 | $1.10 | $11,000.00 |
DisclosureSEC source: 0001493152-17-014245 · form4.xml · nonDerivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 21:57 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 45,000 | $1.07 | $48,298.50 |
DisclosureSEC source: 0001493152-17-013958 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,790,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on November 28, 2017. Accordingly, Reporting Person beneficially owned 4,790,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| November 21, 2017 Filed Nov 29, 2017 21:55 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 45,000 | $1.21 | $54,468.00 |
DisclosureSEC source: 0001493152-17-013956 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,835,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 45,000 shares of Issuer common stock on November 21, 2017. Accordingly, Reporting Person beneficially owned 4,835,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 16:54 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.13 | $28,295.00 |
DisclosureSEC source: 0001493152-17-012078 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,880,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 24, 2017. Accordingly, Reporting Person beneficially owned 4,880,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 16:54 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.14 | $28,455.00 |
DisclosureSEC source: 0001493152-17-012078 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,880,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 24, 2017. Accordingly, Reporting Person beneficially owned 4,880,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 17, 2017 Filed Oct 25, 2017 19:54 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.16 | $28,917.50 |
DisclosureSEC source: 0001493152-17-012045 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,930,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 17, 2017. Accordingly, Reporting Person beneficially owned 4,930,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 17, 2017 Filed Oct 25, 2017 19:54 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.17 | $29,217.50 |
DisclosureSEC source: 0001493152-17-012045 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 4,930,399 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 17, 2017. Accordingly, Reporting Person beneficially owned 4,930,399 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 15, 2017 Filed Oct 17, 2017 21:51 UTC |
Himelfarb YehezkelDirector · COO and General Manager
|
GrantStock Option (Right to Buy) · Derivative | 1,087,627 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001493152-17-011739 · form4.xml · derivative · entry 1 Himelfarb Yehezkel · CIK 0001689912 · Director · COO and General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,627 Underlying: Common Stock, par value $0.01 per share · 1,087,627 shares Expires 2027-10-15 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 22:26 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.39 | $34,727.50 |
DisclosureSEC source: 0001493152-17-011518 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. (2 Disclosed balance after: 5,020,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 10, 2017. Accordingly, Reporting Person beneficially owned 5,020,409 shares of Issuer common stock following the reported transactions. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 22:26 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.37 | $34,177.50 |
DisclosureSEC source: 0001493152-17-011518 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,020,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on October 10, 2017. Accordingly, Reporting Person beneficially owned 5,020,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 09, 2017 Filed Oct 10, 2017 22:21 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 16,600 | $1.50 | $24,900.00 |
DisclosureSEC source: 0001493152-17-011465 · form4.xml · nonDerivative · entry 2 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,390 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 33,700 shares of Issuer common stock on October 5, 2017 and October 9, 2017. Accordingly, Reporting Person beneficially owned 1,558,390 shares of Issuer common stock following the reported transactions. Read SEC document |
| October 05, 2017 Filed Oct 10, 2017 22:21 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 17,100 | $1.50 | $25,679.07 |
DisclosureSEC source: 0001493152-17-011465 · form4.xml · nonDerivative · entry 1 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,390 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 33,700 shares of Issuer common stock on October 5, 2017 and October 9, 2017. Accordingly, Reporting Person beneficially owned 1,558,390 shares of Issuer common stock following the reported transactions. Read SEC document |
| October 05, 2017 Filed Oct 10, 2017 22:17 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 22,000 | $1.49 | $32,797.60 |
DisclosureSEC source: 0001493152-17-011463 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,070,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 22,000 shares of Issuer common stock on October 5, 2017. Accordingly, Reporting Person beneficially owned 5,070,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 18:06 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 3,000 | $1.48 | $4,440.00 |
DisclosureSEC source: 0001493152-17-011297 · form4.xml · nonDerivative · entry 3 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,092,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 53,000 shares of Issuer common stock on October 3, 2017 and October 4, 2017. Accordingly, Reporting Person beneficially owned 5,092,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 18:06 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.17 | $29,337.50 |
DisclosureSEC source: 0001493152-17-011297 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,092,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 53,000 shares of Issuer common stock on October 3, 2017 and October 4, 2017. Accordingly, Reporting Person beneficially owned 5,092,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 18:06 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.19 | $29,707.50 |
DisclosureSEC source: 0001493152-17-011297 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,092,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 53,000 shares of Issuer common stock on October 3, 2017 and October 4, 2017. Accordingly, Reporting Person beneficially owned 5,092,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 16:53 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.23 | $30,682.50 |
DisclosureSEC source: 0001493152-17-011018 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,145,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on September 26, 2017. Accordingly, Reporting Person beneficially owned 5,145,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 16:53 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.25 | $31,217.50 |
DisclosureSEC source: 0001493152-17-011018 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,145,409 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 50,000 shares of Issuer common stock on September 26, 2017. Accordingly, Reporting Person beneficially owned 5,145,409 shares of Issuer common stock following the reported transactions. F2 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 15:42 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.18 | $29,380.00 |
DisclosureSEC source: 0001493152-17-010767 · form4.xml · nonDerivative · entry 2 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,195,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 15:42 UTC |
Bornstein YosephDirector · 10% owner
|
SaleCommon Stock | 25,000 | $1.19 | $29,852.50 |
DisclosureSEC source: 0001493152-17-010767 · form4.xml · nonDerivative · entry 1 Bornstein Yoseph · CIK 0001690100 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LSA- LifeScience Accelerator Ltd. Disclosed balance after: 5,220,409 F1 · ownership.nature: Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 200 | $1.32 | $264.00 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 15 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 7,490 | $1.31 | $9,811.90 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 14 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 1,471 | $1.31 | $1,919.66 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 13 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 6,500 | $1.30 | $8,450.00 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 12 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 9,001 | $1.30 | $11,656.30 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 11 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 6,463 | $1.29 | $8,337.27 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 10 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 11,083 | $1.29 | $14,241.66 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 9 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 14,400 | $1.28 | $18,432.00 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 8 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 1,200 | $1.28 | $1,530.00 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 7 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 27,384 | $1.27 | $34,777.68 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 6 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
| September 15, 2017 Filed Sep 25, 2017 21:48 UTC |
Shoham MosheDirector
|
SaleCommon Stock | 400 | $1.27 | $507.00 |
DisclosureSEC source: 0001493152-17-010887 · form4.xml · nonDerivative · entry 5 Shoham Moshe · CIK 0001690161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,592,090 F1 · balance_after: Reporting Person, through his Rule 10b5-1 trading plan, sold an aggregate of 250,000 shares of Issuer common stock on September 15, 2017. Accordingly, Reporting Person beneficially owned 1,592,090 shares of Issuer common stock following the reported transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.